Balance Sheet Account Detail (Tables)

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Cash And Cash Equivalent Marketable Securities Unrealized Gain Table

The following is a summary of our “cash and cash equivalents” and “marketable securities”:

											Marketable Securities
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated fair Value		Cash and cash equivalents			Current		Long Term
March 31, 2015
Bank deposits	$	56,395	$	—	$	—	$	56,395	$	56,395		$	—	$	—
Money market funds	66,970		—		—		66,970		66,970			—		—
Bank CDs	246		—		—		246		—			246		—
Mutual funds	3,062		—		—		3,062		—			3,062		—
Total cash and equivalents and marketable securities	$	126,673	$	—	$	—	$	126,673	$	123,365		$	3,308	$	—
December 31, 2014
Bank deposits	$	62,997	$	—	$	—	$	62,997	$	62,997		$	—	$	—
Money market funds	66,945		—		—		66,945		66,945			—		—
Bank CDs	244		—		—		244		—			244		—
Mutual funds	3,062		—		—		3,062		—			3,062		—
Total cash and equivalents and marketable securities	$	133,248	$	—	$	—	$	133,248	$	129,942		$	3,306	$	—

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consist of the following:

	March 31, 2015			December 31, 2014
Computer hardware and software	$	3,705		$	3,616
Laboratory equipment	657			643
Office furniture	347			344
Leasehold improvements	2,860			2,847
Property and equipment, at cost	7,569			7,450
(Less): Accumulated depreciation	(6,256		)	(6,045		)
Property and equipment, net of accumulated depreciation	$	1,313		$	1,405

Components of Inventories

“Inventories” consist of the following:

	March 31, 2015		December 31, 2014
Raw materials	$	1,054	$	1,507
Work-in-process*	5,018		3,979
Finished goods	3,007		3,714
Inventories	$	9,079	$	9,200

*We have contractual commitments to receive $6.4 million of raw materials for the future manufacture of ZEVALIN (representing strategic long-term supply), with expected delivery in the fourth quarter of 2015. Inventory at March 31, 2015 includes $0.8 million of ZEVALIN work-in-progress inventory (representing packaged, but unlabeled vials) with expiry in December 2017. We expect to sell this existing and committed ZEVALIN inventory over the next few years. However, if our forecasted ZEVALIN sales or production strategy changes, it could result in a charge in that period to “cost of product sales (excludes amortization of intangible assets)” within the Condensed Consolidated Statements of Operations.

Schedule of Other Receivables

“Other receivables” consist of the (i) amounts we expect to be refunded from taxing authorities for our income taxes paid, primarily relating to fiscal year 2012, (ii) amounts we expect to be reimbursed from certain third-parties for incurred research and development expenses, and (iii) legal expenses to be reimbursed from our insurance carrier.

	March 31, 2015		December 31, 2014
Income tax receivable	$	1,658	$	1,387
Reimbursements due from insurance carrier (see Note 15)	1,746		—
Research and development expenses - reimbursements due	4,510		4,102
Other receivables	$	7,914	$	5,489

Components of Intangible Assets Net of Accumulated Amortization

“Intangible assets, net of accumulated amortization” consist of the following:

			March 31, 2015
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount		Full Amortization Period (months)	Remaining Amortization Period (months)
MARQIBO IPR&D (NHL indication)	$	17,600	$	—		$	—		$	—		$	17,600	n/a	n/a
EVOMELA IPR&D	7,700		—			—			—			7,700		n/a	n/a
BELEODAQ distribution rights	25,000		(1,407		)	—			—			23,593		160	151
MARQIBO distribution rights	26,900		(5,304		)	—			—			21,596		81	60
FOLOTYN distribution rights	118,400		(22,391		)	—			—			96,009		152	122
ZEVALIN distribution rights – U.S.	41,900		(28,002		)	—			—			13,898		123	48
ZEVALIN distribution rights – Ex-U.S.	23,490		(7,199		)	(4,452		)	—			11,839		96	60
FUSILEV distribution rights*	16,778		(7,058		)	—			(7,160		)	2,560		56	9
FOLOTYN out-license**	27,900		(7,066		)	—			(1,023		)	19,811		110	88
Total intangible assets	$	305,668	$	(78,427	)	$	(4,452	)	$	(8,183	)	$	214,606

* On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, and on February 27, 2015, we filed a Notice of Appeal of that decision. On March 6, 2015, the Court of Appeals for the Federal Circuit temporarily enjoined Sandoz International from launching its proposed generic levo-leucovorin products. On April 8, 2015, the Court of Appeals for the Federal Circuit lifted this temporary injunction, removing the last remaining barrier to Sandoz's generic launch, which commenced on April 27, 2015. These events represented a “triggering event” under applicable GAAP for purposes of evaluating our FUSILEV distribution rights' recoverability as of March 31, 2015. Our impairment evaluation resulted in a $7.2 million impairment charge (non-cash) in the first quarter of 2015, and accelerated amortization expense recognition over the remainder of 2015 for the remaining $2.6 million net book value of FUSILEV distribution rights.

** On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., FOLOTYN rights). We determined that an impairment charge (non-cash) of the FOLOTYN out-license rights to Mundipharma of $1.0 million resulted from this amendment.

			December 31, 2014
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount
MARQIBO IPR&D (NHL indication)	$	17,600	$	—		$	—		$	—		$	17,600
EVOMELA IPR&D	7,700		—			—			—			7,700
BELEODAQ distribution rights	25,000		(937		)	—			—			24,063
MARQIBO distribution rights	26,900		(4,225		)	—			—			22,675
FOLOTYN distribution rights	118,400		(20,030		)	—			—			98,370
ZEVALIN distribution rights – U.S.	41,900		(27,134		)	—			—			14,766
ZEVALIN distribution rights – Ex-U.S.	23,490		(7,402		)	(2,162		)	—			13,926
FUSILEV distribution rights	16,778		(6,270		)	—			—			10,508
FOLOTYN out-license	27,900		(6,385		)	—			(1,023		)	20,492
Total intangible assets	$	305,668	$	(72,383	)	$	(2,162	)	$	(1,023	)	$	230,100

Estimated Intangible Asset Amortization Expense

Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the remainder of 2015 and the five succeeding fiscal years and thereafter is as follows:

Years Ending December 31,
Remainder of 2015	$	20,712
2016	24,203
2017	24,203
2018	24,203
2019	21,597
2020	15,714
2021 and thereafter	58,674
	$	189,306

Schedule of Goodwill

“Goodwill” is comprised of the following (by source):

	March 31, 2015			December 31, 2014
Acquisition of Talon	$	10,526		$	10,526
Acquisition of ZEVALIN Ex-U.S. distribution rights	2,525			2,525
Acquisition of Allos	5,346			5,346
Foreign currency exchange translation effects	(448		)	(202		)
Goodwill	$	17,949		$	18,195

Summary of Other Assets

“Other assets” are comprised of the following:

	March 31, 2015		December 31, 2014
Equity securities and secured promissory note – CASI (see Note 10)*	$	9,254	$	8,501
Supplies	239		234
2018 Convertible Notes issuance costs**	2,000		2,171
Executive officer life insurance – cash surrender value	7,315		6,958
Other assets	$	18,808	$	17,864

* These equity securities were excluded from “marketable securities” (see Note 3(a)) due to our intent to hold these securities for at least one year beyond March 31, 2015, as discussed in Note 10. Gross unrealized gains from these equity securities (recognized through “other comprehensive income”) were $0.8 million for the three months ended March 31, 2015.

** In April 2015, the FASB issued Accounting Standards Update ("ASU") 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. However, ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs.  ASU 2015-03 is effective for our annual and interim reporting periods beginning January 1, 2016.  Accordingly, we will record a reclassification of our 2018 Convertible Notes issuance costs, from “other assets” to “convertible senior notes” within our Consolidated Balance Sheets, beginning January 1, 2016.

Schedule of Accounts Payable and Other Accrued Liabilities

“Accounts payable and other accrued liabilities” are comprised of the following:

	March 31, 2015		December 31, 2014
Trade accounts payable and other accrueds	$	22,386	$	24,571
Accrued rebates	43,104		41,782
Accrued product royalty	2,849		5,182
Allowance for returns	1,381		1,135
Accrued data and distribution fees	3,650		3,952
Accrued GPO administrative fees	3,254		3,222
Inventory management fee	1,103		1,110
Allowance for chargebacks	4,426		4,040
Accounts payable and other accrueds	$	82,153	$	84,994

Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets specifically for GTN estimates (see Note 2(i)) are as follows:

Description	Rebates and Chargebacks			Data and Distribution, GPO Fees, and Inventory Management Fees			Returns
Balance as of December 31, 2013	$	33,967		$	5,373		$	2,900
Add: provisions	76,636			21,330			(78		)
(Less): credits or actual allowances	(64,781		)	(18,419		)	(1,687		)
Balance as of December 31, 2014	45,822			8,284			1,135
Add: provisions	24,926			6,002			583
(Less): credits or actual allowances	(23,218		)	(6,279		)	(337		)
Balance as of March 31, 2015	$	47,530		$	8,007		$	1,381

Deferred Revenue, by Arrangement, Disclosure

Deferred revenue (including current and long-term) is comprised of the following:

	March 31, 2015	December 31, 2014
CASI out-license (see Note 10)	9,959	9,959
FUSILEV deferred revenue*	7,039	—
Dr. Reddy's deferred revenue	463	—
Deferred revenue	17,461	9,959

* We deferred revenue recognition for $7.0 million related to certain FUSILEV product shipments in the first quarter of 2015 that did not meet our revenue recognition criteria (see Note 2(i)(a)). The deferral resulted from inability to estimate rebates that will be offered to compete with the generic levo-leucovorin products later in 2015. 

Summary of Other Long-Term Liabilities

Other long-term liabilities are comprised of the following:

	March 31, 2015		December 31, 2014
Accrued executive deferred compensation	$	5,593	$	4,694
Deferred rent (non-current portion)	321		364
Business acquisition liability	300		300
Other tax liabilities	730		730
Other long-term liabilities	$	6,944	$	6,088